Commencing 1 March 2022 Lagevrio® (molnupiravir) has been listed on the Pharmaceutical Benefits Scheme (PBS) Section 85 program as an Authority Required (Streamlined) benefit for patients with mild-moderate COVID 19 who have a high risk for developing severe disease, reducing the need for admission to hospital.

The Pharmaceutical Benefits Advisory Committee (PBAC) undertook an expedited consideration of a sponsor submission to add molnupiravir (Lagevrio®) to the Pharmaceutical Benefits Scheme (PBS) for use in treating patients with mild to moderate COVID-19 who are at risk of developing severe disease requiring hospitalisation.

The expedited consideration by PBAC recognises the urgent public health need related to the prevention, management, or treatment of SARS-CoV-2 infections.

The PBAC recommended the listing on the PBS of molnupiravir as a General Schedule, Authority Required (Streamlined) benefit.

The Lagevrio® (molnupiravir) PBS Factsheet is available here